Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study of SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Trial Profile

A Phase Ib Study of SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SEL-120 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Sponsors Ryvu Therapeutics
  • Most Recent Events

    • 10 Dec 2019 Trial design released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Nov 2019 According to Ryvu Therapeutics media release, data from this study will be presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, FL, taking place from December 7-10, 2019.
    • 06 Sep 2019 According to a Selvita media release, the first patient has been enrolled and dosed in this trial. Preliminary results anticipated to share with the oncology community in 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top